'On consolidated basis

Quarter ended September 2025 compared with Quarter ended September 2024.

Net sales (including other operating income) of Zydus Lifesciences has increased 16.92% to Rs 6123.2 crore.  Sales of pharmaceuticals segment has gone up 15.31% to Rs 5,474.30 crore (accounting for 89.40% of total sales).  Sales of Consumer Products segment has gone up 32.56% to Rs 648.90 crore (accounting for 10.60% of total sales).  

Profit before interest, tax and other unallocable items (PBIT) has jumped 35.46% to Rs 1,721.60 crore.  PBIT of pharmaceuticals segment rose 38.56% to Rs 1,738.80 crore (accounting for 101.00% of total PBIT).  PBIT of Consumer Products reported loss of Rs 17.20 crore compared to profit of Rs 16.00 crore.  

PBIT margin of pharmaceuticals segment rose from 26.43% to 31.76%.  PBIT margin of Consumer Products segment fell from 3.27% to 2.65%.  Ove...

• 

  (13-Jan-2026)

  Tata Consultancy Services

  Revenue up 4.9% YoY to Rs 67087 crore in Q3FY2026
• 

  (12-Jan-2026)

  Krishana Phoschem

  Revenue up 116.8% YoY to Rs 659 crore in Q3FY2026
• 

  (11-Jan-2026)

  Avenue Supermarts

  Revenue up 13.3% YoY to Rs 18100.9 crore, Net profit up 18.3% yoy to Rs 855.9 crore in Q3FY2026
• 

  (09-Jan-2026)

  Elecon Engineering Company

  Sales up 4%, net down 33%